Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy

References

• Wang L, Lu B, He M, et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:1. doi: 10.3389/fpubh.2022.811044.
   Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–19.
   PubMed Web of Science ®Google Scholar
• Krieger KL, Gohlke JH, Lee KJ, et al. Repair-assisted damage detection reveals biological disparities in prostate cancer between African Americans and European Americans. Cancers (Basel). 2022;14(4):1012. doi: 10.3390/cancers14041012.
   PubMed Web of Science ®Google Scholar
• Plym A, Zhang Y, Stopsack KH, et al. Family history of prostate and breast cancer integrated with a polygenic risk score identifies men at highest risk of dying from prostate cancer before age 75 years. Clin Cancer Res. 2022;28(22):4926–4933. doi: 10.1158/1078-0432.CCR-22-1723.
   PubMed Web of Science ®Google Scholar
• Shore N. Management of early-stage prostate cancer. Am J Manag Care. 2014;20(12 Suppl):S260–S72.
   PubMed Web of Science ®Google Scholar
• Gillessen S, Bossi A, Davis ID, et al. Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022. Eur Urol. 2023;83(3):267–293. doi: 10.1016/j.eururo.2022.11.002.
   PubMed Web of Science ®Google Scholar
• Sandhu S, Moore CM, Chiong E, et al. Prostate cancer. Lancet. 2021;398(10305):1075–1090. doi: 10.1016/S0140-6736(21)00950-8.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic Hormone-Sensitive prostate cancer. Prostate. 2022;82(13):1237–1247. doi: 10.1200/JCO.19.00799.
   PubMedGoogle Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic Hormone-Sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087. doi: 10.1200/JCO.2017.75.3657.
   PubMed Web of Science ®Google Scholar
• Wang L, Dehm SM, Hillman DW, et al. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018;29(2):352–360. doi: 10.1093/annonc/mdx689.
   PubMed Web of Science ®Google Scholar
• Shih TC, Liu R, Wu CT, et al. Targeting galectin-1 impairs castration-resistant prostate cancer progression and invasion. Clin Cancer Res. 2018;24(17):4319–4331. doi: 10.1158/1078-0432.CCR-18-0157.
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. doi: 10.1056/NEJMoa1911440.
   PubMed Web of Science ®Google Scholar
• Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34(9):772–782. doi: 10.1016/j.annonc.2023.06.009.
   PubMed Web of Science ®Google Scholar
• Stark JR, Perner S, Stampfer MJ, et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009;27(21):3459–3464. doi: 10.1200/JCO.2008.20.4669.
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Izumi K, Kadono Y, et al. Prognosis of patients with prostate cancer and Middle range prostate - specific antigen levels of 20 - 100 ng/mL. Int Braz J Urol. 2019;45(1):61–67. doi: 10.1590/S1677-5538.IBJU.2018.0143.
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Albreht T, Basu P, et al. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19(9):562–572. doi: 10.1038/s41585-022-00638-6.
   PubMed Web of Science ®Google Scholar
• Williams IS, McVey A, Perera S, et al. Modern paradigms for prostate cancer detection and management. Med J Aust. 2022;217(8):424–433. doi: 10.5694/mja2.51722.
   PubMed Web of Science ®Google Scholar
• Sun C, Yang D, Zhu J, et al. Modified the 8th AJCC staging system for patients with advanced prostate cancer: a study based on SEER database. BMC Urol. 2022;22(1):185. doi: 10.1186/s12894-022-01135-z.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998;280(11):969–974. doi: 10.1001/jama.280.11.969.
   PubMed Web of Science ®Google Scholar
• Chang AJ, Autio KA, Roach M, 3rd, et al. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308–323. doi: 10.1038/nrclinonc.2014.68.
   PubMed Web of Science ®Google Scholar
• Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47(3):609–615. doi: 10.1016/s0360-3016(00)00578-2.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009;101(12):878–887. doi: 10.1093/jnci/djp122.
   PubMedGoogle Scholar
• Huang J, Vicini FA, Williams SG, et al. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer? Int J Radiat Oncol Biol Phys. 2012;83(4):1141–1148. doi: 10.1016/j.ijrobp.2011.09.043.
   PubMed Web of Science ®Google Scholar
• Yossepowitch O, Eggener SE, Bianco FJ, Jr., et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007;178(2):493–499; discussion 499. doi: 10.1016/j.juro.2007.03.105.
   PubMed Web of Science ®Google Scholar
• Gosselaar C, Kranse R, Roobol MJ, et al. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate. 2008;68(9):985–993. doi: 10.1002/pros.20759.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Alshalalfa M, Davicioni E, et al. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol. 2015;68(4):555–567. doi: 10.1016/j.eururo.2015.04.033.
   PubMed Web of Science ®Google Scholar
• Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41(6):781–793. doi: 10.1016/j.humpath.2010.02.011.
   PubMed Web of Science ®Google Scholar
• Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994;152(5 Pt 2):1709–1713. doi: 10.1016/s0022-5347(17)32368-6.
   PubMed Web of Science ®Google Scholar
• Faisal FA, Sundi D, Tosoian JJ, et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol. 2016;70(1):14–17. doi: 10.1016/j.eururo.2015.09.031.
   PubMed Web of Science ®Google Scholar
• Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79–92. doi: 10.1038/s41585-020-00400-w.
   PubMed Web of Science ®Google Scholar
• Mills IG. Molecular subtyping of prostate cancer: a partnership model. Eur Urol. 2015;68(4):568–569. doi: 10.1016/j.eururo.2015.05.012.
   PubMed Web of Science ®Google Scholar
• Galletti G, Matov A, Beltran H, et al. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014;5(1):5548. doi: 10.1038/ncomms6548.
   PubMedGoogle Scholar
• Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011;19(5):664–678. doi: 10.1016/j.ccr.2011.04.010.
   PubMed Web of Science ®Google Scholar
• Scheving LA. Primary amino acid sequence similarity between human epidermal growth factor-urogastrone, human pancreatic secretory trypsin inhibitor, and members of porcine secretin family. Arch Biochem Biophys. 1983;226(2):411–413. doi: 10.1016/0003-9861(83)90309-0.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25(4):398–406. doi: 10.1097/CCO.0b013e3283622c1b.
   PubMed Web of Science ®Google Scholar
• The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–1025. doi: 10.1016/j.cell.2015.10.025.
   PubMed Web of Science ®Google Scholar
• Baena E, Shao Z, Linn DE, et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev. 2013;27(6):683–698. doi: 10.1101/gad.211011.112.
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–522. doi: 10.1016/j.ccr.2010.03.017.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–567. doi: 10.1016/j.ccr.2010.11.015.
   PubMed Web of Science ®Google Scholar
• Chandran UR, Ma C, Dhir R, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer. 2007;7(1):64. doi: 10.1186/1471-2407-7-64.
   PubMedGoogle Scholar
• Schaeffer EM, Marchionni L, Huang Z, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008;27(57):7180–7191. doi: 10.1038/onc.2008.327.
   PubMed Web of Science ®Google Scholar
• Massie CE, Mills IG, Lynch AG. The importance of DNA methylation in prostate cancer development. J Steroid Biochem Mol Biol. 2017;166:1–15. doi: 10.1016/j.jsbmb.2016.04.009.
   PubMed Web of Science ®Google Scholar
• Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10(4):321–330. doi: 10.1016/j.ccr.2006.09.005.
   PubMed Web of Science ®Google Scholar
• Correction For G, et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2019;116(28):14386–14387.
   PubMed Web of Science ®Google Scholar
• An J, Wang C, Deng Y, et al. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014;6(4):657–669. doi: 10.1016/j.celrep.2014.01.013.
   PubMed Web of Science ®Google Scholar
• Geng C, Rajapakshe K, Shah SS, et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014;74(19):5631–5643. doi: 10.1158/0008-5472.CAN-14-0476.
   PubMedGoogle Scholar
• Chen Y, Chi P, Rockowitz S, et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med. 2013;19(8):1023–1029. doi: 10.1038/nm.3216.
   PubMed Web of Science ®Google Scholar
• Yu J, Yu J, Mani RS, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010;17(5):443–454. doi: 10.1016/j.ccr.2010.03.018.
   PubMed Web of Science ®Google Scholar
• Boysen G, Rodrigues DN, Rescigno P, et al. SPOP-Mutated/CHD1-Deleted lethal prostate cancer and abiraterone sensitivity. Clin Cancer Res. 2018;24(22):5585–5593. doi: 10.1158/1078-0432.CCR-18-0937.
   PubMed Web of Science ®Google Scholar
• Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. J Clin Oncol Precis Oncol. 2017;2017(1):1–16 doi: 10.1200/PO.17.00029.
   Google Scholar
• Guo ZQ, Zheng T, Chen B, et al. Small-molecule targeting of E3 ligase adaptor SPOP in kidney cancer. Cancer Cell. 2016;30(3):474–484. doi: 10.1016/j.ccell.2016.08.003.
   PubMed Web of Science ®Google Scholar
• Bernasocchi T, El Tekle G, Bolis M, et al. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Nat Commun. 2021;12(1):734. doi: 10.1038/s41467-020-20820-x.
   PubMed Web of Science ®Google Scholar
• You S, Knudsen BS, Erho N, et al. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res. 2016;76(17):4948–4958. doi: 10.1158/0008-5472.CAN-16-0902.
   PubMed Web of Science ®Google Scholar
• Levine DM, Haynor DR, Castle JC, et al. Pathway and gene-set activation measurement from mRNA expression data: the tissue distribution of human pathways. Genome Biol. 2006;7(10):R93. doi: 10.1186/gb-2006-7-10-r93.
   PubMed Web of Science ®Google Scholar
• Brunet JP, Tamayo P, Golub TR, et al. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004;101(12):4164–4169. doi: 10.1073/pnas.0308531101.
   PubMed Web of Science ®Google Scholar
• Thysell E, Ylitalo EB, Jernberg E, et al. A systems approach to prostate cancer classification-letter. Cancer Res. 2017;77(24):7131–7132. doi: 10.1158/0008-5472.CAN-16-3231.
   PubMed Web of Science ®Google Scholar
• You S, Freeman MR. A systems approach to prostate cancer classification-response. Cancer Res. 2017;77(24):7133–7135. doi: 10.1158/0008-5472.CAN-17-0239.
   PubMed Web of Science ®Google Scholar
• Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15(12):701–711. doi: 10.1038/nrc4016.
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–1167. doi: 10.1200/JCO.2008.18.1370.
   PubMed Web of Science ®Google Scholar
• Zhao SG, Chang SL, Erho N, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017;3(12):1663–1672. doi: 10.1001/jamaoncol.2017.0751.
   PubMed Web of Science ®Google Scholar
• Smith MR, Antonarakis ES, Ryan CJ, et al. Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol. 2016;70(6):963–970. doi: 10.1016/j.eururo.2016.04.023.
   PubMed Web of Science ®Google Scholar
• Karthaus WR, Iaquinta PJ, Drost J, et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 2014;159(1):163–175. doi: 10.1016/j.cell.2014.08.017.
   PubMed Web of Science ®Google Scholar
• Mian OY, Tendulkar RD, Abazeed ME. The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin. Transl Cancer Res. 2017;6(Suppl 9):S1441–S1445. doi: 10.21037/tcr.2017.10.49.
   PubMedGoogle Scholar
• Ylitalo EB, Thysell E, Jernberg E, et al. Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response. Eur Urol. 2017;71(5):776–787. doi: 10.1016/j.eururo.2016.07.033.
   PubMed Web of Science ®Google Scholar
• Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol. 2014;6(1):3–14. doi: 10.1177/1756287213509677.
   PubMedGoogle Scholar
• Frey BJ, Dueck D. Clustering by passing messages between data points. Science. 2007;315(5814):972–976. doi: 10.1126/science.1136800.
   PubMed Web of Science ®Google Scholar
• Pérez-Guaita D, Kuligowski J, Lendl B, et al. Assessment of discriminant models in infrared imaging using constrained repeated random sampling - cross validation. Anal Chim Acta. 2018;1033:156–164. doi: 10.1016/j.aca.2018.05.019.
   PubMed Web of Science ®Google Scholar
• Thysell E, Vidman L, Ylitalo EB, et al. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor. Mol Oncol. 2019;13(8):1763–1777. doi: 10.1002/1878-0261.12526.
   PubMed Web of Science ®Google Scholar
• Cai C, He HH, Chen S, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20(4):457–471. doi: 10.1016/j.ccr.2011.09.001.
   PubMed Web of Science ®Google Scholar
• Gao S, Gao Y, He HH, et al. Androgen receptor tumor suppressor function is mediated by recruitment of retinoblastoma protein. Cell Rep. 2016;17(4):966–976. doi: 10.1016/j.celrep.2016.09.064.
   PubMed Web of Science ®Google Scholar
• Yang S, Jiang M, Grabowska MM, et al. Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo. Oncotarget. 2016;7(43):70404–70419. doi: 10.18632/oncotarget.11879.
   PubMedGoogle Scholar
• Korsen JA, Kalidindi TM, Khitrov S, et al. Molecular imaging of neuroendocrine prostate cancer by targeting Delta-like ligand 3. J Nucl Med. 2022;63(9):1401–1407. doi: 10.2967/jnumed.121.263221.
   PubMed Web of Science ®Google Scholar
• Chen M, Lingadahalli S, Narwade N, et al. TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation. EMBO Rep. 2022;23(8):e53468.
   PubMed Web of Science ®Google Scholar
• Wierstra I, Alves J. FOXM1, a typical proliferation-associated transcription factor. Biol Chem. 2007;388(12):1257–1274. doi: 10.1515/BC.2007.159.
   PubMed Web of Science ®Google Scholar
• Chesnokov MS, Halasi M, Borhani S, et al. Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells. Cell Death Dis. 2021;12(7):704. doi: 10.1038/s41419-021-03978-0.
   PubMed Web of Science ®Google Scholar
• Barakat DJ, Zhang J, Barberi T, et al. CCAAT/enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells. Oncogene. 2015;34(48):5912–5922. doi: 10.1038/onc.2015.41.
   PubMed Web of Science ®Google Scholar
• Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10(1):51–57. doi: 10.1038/nrc2772.
   PubMed Web of Science ®Google Scholar
• Coppé JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5(1):99–118. doi: 10.1146/annurev-pathol-121808-102144.
   PubMed Web of Science ®Google Scholar
• Iglesias-Gato D, Thysell E, Tyanova S, et al. The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications. Clin Cancer Res. 2018;24(21):5433–5444. doi: 10.1158/1078-0432.CCR-18-1229.
   PubMed Web of Science ®Google Scholar
• Ge G, Han Y, Zhang J, et al. Single-Cell RNA-seq reveals a developmental hierarchy Super-Imposed over subclonal evolution in the cellular ecosystem of prostate cancer. Adv Sci (Weinh). 2022;9(15):e2105530.
   PubMedGoogle Scholar
• Peng S, Hu P, Xiao YT, et al. Single-Cell analysis reveals EP4 as a target for restoring T-Cell infiltration and sensitizing prostate cancer to immunotherapy. Clin Cancer Res. 2022;28(3):552–567. doi: 10.1158/1078-0432.CCR-21-0299.
   PubMed Web of Science ®Google Scholar
• Han H, Lee HH, Choi K, et al. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype. Prostate Cancer Prostatic Dis. 2021;24(4):1080–1092. doi: 10.1038/s41391-021-00364-x.
   PubMed Web of Science ®Google Scholar
• Henry GH, Malewska A, Joseph DB, et al. A cellular anatomy of the normal adult human prostate and prostatic urethra. Cell Rep. 2018;25(12):3530–3542 e5. doi: 10.1016/j.celrep.2018.11.086.
   PubMed Web of Science ®Google Scholar
• Terry S, Nicolaiew N, Basset V, et al. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer. Cancer. 2015;121(9):1422–1430. doi: 10.1002/cncr.29233.
   PubMed Web of Science ®Google Scholar
• Lee JK, Bangayan NJ, Chai T, et al. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A. 2018;115(19):E4473–e82.
   PubMed Web of Science ®Google Scholar
• Spetsieris N, Boukovala M, Patsakis G, et al. Neuroendocrine and aggressive-variant prostate cancer. Cancers (Basel). 2020;12(12):3792. doi: 10.3390/cancers12123792.
   PubMed Web of Science ®Google Scholar
• Islam R, Mishra J, Polavaram NS, et al. Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance. Cell Rep. 2022;40(3):111097. doi: 10.1016/j.celrep.2022.111097.
   PubMed Web of Science ®Google Scholar
• von Amsberg G, Zilles M, Mansour W, et al. Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in aggressive variant of metastatic castration-resistant prostate cancer. Int J Mol Sci. 2022;23(23):14948.
   Web of Science ®Google Scholar
• Xu H, Wang F, Li H, et al. Prostatic acid phosphatase (PAP) predicts prostate cancer progress in a Population-Based study: the renewal of PAP? Dis Markers. 2019;2019:7090545–7090510. doi: 10.1155/2019/7090545.
   PubMed Web of Science ®Google Scholar
• Karanika S, Karantanos T, Kurosaka S, et al. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Mol Cancer. 2015;14(1):122. doi: 10.1186/s12943-015-0395-0.
   PubMedGoogle Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924–940. doi: 10.1016/j.immuni.2019.03.024.
   PubMed Web of Science ®Google Scholar
• Monteran L, Erez N. The dark side of fibroblasts: cancer-Associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. doi: 10.3389/fimmu.2019.01835.
   PubMed Web of Science ®Google Scholar
• Meng J, Zhou Y, Lu X, et al. Immune response drives outcomes in prostate cancer: implications for immunotherapy. Mol Oncol. 2021;15(5):1358–1375. doi: 10.1002/1878-0261.12887.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Paskeh MDA, Okina E, et al. Molecular landscape of LncRNAs in prostate cancer: a focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res. 2022;41(1):214. doi: 10.1186/s13046-022-02406-1.
   PubMed Web of Science ®Google Scholar
• Wang F, Wu L, Yin L, et al. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer. Clin Transl Med. 2022;12(6):e901.
   PubMed Web of Science ®Google Scholar
• Jagodinsky JC, Bates AM, Clark PA, et al. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization. J Immunother Cancer. 2022;10(10):e005103. doi: 10.1136/jitc-2022-005103.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol. 2019;75(3):378–382. doi: 10.1016/j.eururo.2018.10.009.
   PubMed Web of Science ®Google Scholar
• Abida W, Cheng ML, Armenia J, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471–478. doi: 10.1001/jamaoncol.2018.5801.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395–405. doi: 10.1200/JCO.19.01638.
   PubMed Web of Science ®Google Scholar
• García-Aranda M, Redondo M. Targeting protein kinases to enhance the response to anti-PD-1/PD-L1 immunotherapy. Int J Mol Sci. 2019;20(9):2296.
   PubMed Web of Science ®Google Scholar
• Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat. 2019;46:100644. doi: 10.1016/j.drup.2019.100644.
   PubMed Web of Science ®Google Scholar
• van Bussel MTJ, Awada A, de Jonge MJA, et al. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. Br J Cancer. 2021;124(4):728–735. doi: 10.1038/s41416-020-01151-6.
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903. doi: 10.1016/S1470-2045(17)30380-7.
   PubMed Web of Science ®Google Scholar
• Wei Q, Costanzi S, Balasubramanian R, et al. A2B adenosine receptor blockade inhibits growth of prostate cancer cells. Purinergic Signal. 2013;9(2):271–280. doi: 10.1007/s11302-012-9350-3.
   PubMed Web of Science ®Google Scholar
• Diab A, Tannir NM, Bentebibel SE, et al. Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02). Cancer Discov. 2020;10(8):1158–1173. doi: 10.1158/2159-8290.CD-19-1510.
   PubMed Web of Science ®Google Scholar
• Panni RZ, Herndon JM, Zuo C, et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci Transl Med. 2019;11(499):eaau9240. doi: 10.1126/scitranslmed.aau9240.
   PubMed Web of Science ®Google Scholar
• Bansal D, Reimers MA, Knoche EM, et al. Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer. Cancers (Basel). 2021;13(2):334. doi: 10.3390/cancers13020334.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830.e14. doi: 10.1016/j.immuni.2018.03.023.
   PubMed Web of Science ®Google Scholar
• Lu X, Meng J, Zhou Y, et al. MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics. 2020;36(22-23):5539–5541.
   Web of Science ®Google Scholar
• Meng J, Lu X, Jin C, et al. Integrated multi-omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer. Clin Transl Med. 2021;11(12):e655.
   PubMed Web of Science ®Google Scholar
• Singhal A, Cheng CY. Host NAD + metabolism and infections: therapeutic implications. Int Immunol. 2019;31(2):59–67. doi: 10.1093/intimm/dxy068.
   PubMed Web of Science ®Google Scholar
• Tian JJ, Lei CX, Ji H, et al. Role of cyclooxygenase-mediated metabolites in lipid metabolism and expression of some immune-related genes in juvenile grass carp (ctenopharyngodon idellus) fed arachidonic acid. Fish Physiol Biochem. 2017;43(3):703–717. doi: 10.1007/s10695-016-0326-z.
   PubMed Web of Science ®Google Scholar
• Ferreira NS, Tostes RC, Paradis P, et al. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 2021;34(1):15–27. doi: 10.1093/ajh/hpaa137.
   PubMed Web of Science ®Google Scholar
• Ding Z, Wu CJ, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011;470(7333):269–273. doi: 10.1038/nature09677.
   PubMed Web of Science ®Google Scholar
• Comstock CE, Augello MA, Goodwin JF, et al. Targeting cell cycle and hormone receptor pathways in cancer. Oncogene. 2013;32(48):5481–5491. doi: 10.1038/onc.2013.83.
   PubMed Web of Science ®Google Scholar
• Bruxvoort KJ, Charbonneau HM, Giambernardi TA, et al. Inactivation of apc in the mouse prostate causes prostate carcinoma. Cancer Res. 2007;67(6):2490–2496. doi: 10.1158/0008-5472.CAN-06-3028.
   PubMed Web of Science ®Google Scholar
• Dow LE, O’Rourke KP, Simon J, et al. Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell. 2015;161(7):1539–1552. doi: 10.1016/j.cell.2015.05.033.
   PubMed Web of Science ®Google Scholar
• Lin X, Wu Y, Liu F, et al. A germline variant at 8q24 contributes to the serum p2PSA level in a chinese prostate biopsy cohort. Front Oncol. 2021;11:753920. doi: 10.3389/fonc.2021.753920.
   PubMed Web of Science ®Google Scholar
• Hoffmann TJ, Passarelli MN, Graff RE, et al. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. Nat Commun. 2017;8(1):14248. doi: 10.1038/ncomms14248.
   PubMedGoogle Scholar
• Siu MK, Suau F, Chen WY, et al. KLF4 functions as an activator of the androgen receptor through reciprocal feedback. Oncogenesis. 2016;5(12):e282–e282. doi: 10.1038/oncsis.2016.79.
   PubMedGoogle Scholar
• Geng H, Xue C, Mendonca J, et al. Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. Nat Commun. 2018;9(1):4972. doi: 10.1038/s41467-018-07411-7.
   PubMedGoogle Scholar
• Yoon J, Kim M, Posadas EM, et al. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer Prostatic Dis. 2021;24(3):733–742. doi: 10.1038/s41391-021-00325-4.
   PubMed Web of Science ®Google Scholar